January 21, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing new adverse reaction risks for AbbVie’s hepatitis C drug Maviret (glecaprevir + pibrentasvir), Pfizer’s breast cancer med Ibrance (palbociclib), as well as major PD-1 inhibitors - a move that is likely...read more